Cell Line Catalog Development

About Evanoa Bioscience

Evanoa Bioscience is a private, pre-revenue platform company founded in 2019 and headquartered in Alachua, Florida. The company's core asset is a novel, proprietary technology for engineering cell lines (including E. coli, S. cerevisiae, SF9, CHO, and HEK293) to achieve order-of-magnitude improvements in productivity for biologics manufacturing. Its business model revolves around licensing these improved cell lines to partners such as CDMOs, pharmaceutical, and biotechnology companies, as evidenced by its 2023 licensing agreement with Aldevron for specialized E. coli strains used in plasmid DNA production. Evanoa aims to become a key enabler in the biomanufacturing supply chain by providing foundational tools that increase the efficiency and scalability of therapeutic production.

Other Biologics Manufacturing Drugs